as 10-28-2025 4:00pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SCOTTSDALE |
| Market Cap: | 190.7M | IPO Year: | 2021 |
| Target Price: | $12.67 | AVG Volume (30 days): | 153.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.54 - $8.90 | Next Earning Date: | 11-07-2025 |
| Revenue: | $56,397,000 | Revenue Growth: | -27.40% |
| Revenue Growth (this year): | 26.16% | Revenue Growth (next year): | 45.27% |
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
MT Newswires
3 months ago
GlobeNewswire
3 months ago
MT Newswires
4 months ago
GlobeNewswire
4 months ago
TipRanks
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
5 months ago
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.